Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | N/A | -13.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.20 | N/A | -13.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over recent performance but remains committed to their strategic objectives. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.
This earnings report indicates that Krystal Biotech is facing challenges, particularly reflected in their lower-than-expected EPS. The stock's significant drop of 14.06% suggests that investors are reacting negatively to the missed expectations and lack of guidance. The company's focus on long-term growth may help in the future, but immediate concerns are weighing heavily on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025